Longevity drugs: the pipeline tracker
As of Nov. 3, 2026, the FDA has not approved any drug to treat aging itself; candidates such as metformin and rapamycin are still being tested in human trials registered on ClinicalTrials.gov (sources: FDA, ClinicalTrials.gov, checked Nov. 3, 2026).
By Mongevity Desk · About us · Corrections
You hear about rapamycin, metformin, senolytics or NAD+ as "anti-aging" drugs. This tracker puts every study we cover on those candidates in one table, with our A–E evidence grade, so you can tell a result in people from a promise based on mice or cells.
The table fills itself: each time we publish a study on a longevity drug, it appears here with its grade and the reason for it. You can download it as a CSV.
This page explains research; it is not medical advice. Do not start or stop a medicine without talking to your doctor.
Not covered yet: rapamycin, metformin for aging, senolytics and NAD+ boosters. The table groups what we have by topic, so you can see that the GLP-1 studies are about weight and diabetes, not aging itself.
Every study we've graded
- AStrong: large randomized trials or meta-analyses in people, with hard outcomes.
- BGood: randomized trials in people with smaller samples, shorter follow-up or lab markers.
- CModerate: well-done observational studies in people.
- DLimited: small or early studies in people.
- EVery limited: studies in cells or animals only.
| Study | Topic | Evidence | Why this grade | Original paper | Date |
|---|---|---|---|---|---|
| Biological age tests | |||||
| The immune system’s T cell variety drops faster after about age 50 | Aging | C | Very large pooled data set; mostly cross-sectional associations across cohorts with different methods. | Paper | Nov. 3, 2026 |
| A blood-test biological age added little beyond how well older adults function | Aging | C | Two large observational cohorts with the same method; tests a single biological age score and can't show causation. | Paper | Nov. 3, 2026 |
| After weight-loss surgery, the heart’s AI-estimated age slowly drew closer to real age | Aging | C | Large retrospective cohort with repeated ECGs; no non-surgical comparison group and AI-ECG age is a new marker. | Paper | Nov. 3, 2026 |
| GLP-1 drugs (Ozempic, Wegovy, Mounjaro) | |||||
| A daily GLP-1 pill cut body weight by up to 8.7% in a phase 3 trial in Japan | Metabolism | A | Double-blind randomized placebo-controlled phase 3 trial; maker-funded, Japanese adults only. | Paper | Nov. 3, 2026 |
| A triple-hormone injection lowered blood sugar more than semaglutide in a phase 2 trial | Metabolism | B | Randomized phase 2 trial with placebo and an active comparator; short, single-country and run by the drug developer. | Paper | Nov. 3, 2026 |
| A GLP-1/GIP drug helped adults with type 1 diabetes lose weight in a 16-week trial | Metabolism | B | Double-blind randomized placebo-controlled phase 2 trial; small, 16 weeks, and the HbA1c effect was modest. | Paper | Nov. 3, 2026 |
| In schizophrenia with diabetes, a GLP-1 drug was linked to fewer psychiatric admissions | Metabolism | C | Large records study with weighting and active comparators; observational with possible residual confounding and selection bias. | Paper | Nov. 3, 2026 |
| Medicines in old age | |||||
| Stopping blood-thinning medicines in nursing home AFib was linked to higher mortality | Aging | C | Large target trial emulation with Medicare claims; not randomized, very high mortality, unmeasured confounding and claims-based outcomes. | Paper | Nov. 3, 2026 |
| In people 75 and older, a common diabetes drug didn’t look riskier than the alternative | Aging | C | Large real-world cohort with an active comparator and weighting; observational, so residual confounding is possible, and some estimates were imprecise. | Paper | Nov. 3, 2026 |
| When one medicine leads to another: 24 prescribing cascades to watch in older adults | Aging | C | Very large population cohort with an established method; shows timing patterns, not confirmed side effects, in one province. | Paper | Nov. 3, 2026 |
Questions people ask
Is there a drug that slows aging in humans?
As of Nov. 3, 2026, the FDA has not approved any drug to treat aging itself; candidates such as metformin and rapamycin are still being tested in human trials registered on ClinicalTrials.gov (sources: FDA, ClinicalTrials.gov, checked Nov. 3, 2026).
Where the data comes from
- ClinicalTrials.gov, National Institutes of Health: The official registry of clinical trials: phase, status, dates and results, filed by the researchers.
- PubMed, U.S. National Library of Medicine: Every study we grade links to the original journal article.
- U.S. Food and Drug Administration: press announcements: The FDA announces its own approvals, warnings and decisions.
Mongevity explains research. It does not give medical advice.